This is optional continuation round 2 in the same session. Do not restart the task or open a new session.

Codex has produced `.artifacts/a-values-matrix-fix-candidate-v4/research-content.json` after addressing your blocking findings. Independently verify only the following repairs and return a clear `PASS` or `BLOCK` recommendation with exact residual defects:

1. The 14 superseded null `任何TEAE` placeholder rows for lebrikizumab, nemolizumab, abrocitinib, upadacitinib, baricitinib, tapinarof, and roflumilast-cream are removed from both report rows and bound facts/claims. Check that no published/null contradiction remains for these products.
2. Lebrikizumab ADvocate 1 is corrected to NICE TA986 Table 42: lebrikizumab 129/282 (45.7%), placebo 73/141 (51.8%), Week 16, NCT04146363. Verify the new local source extract and SHA binding.
3. The content digest `3c42232e53194820e319696afc7c3e815300718efe3ec0e95028b26ab8d91080` is the application canonical JSON digest, not the raw pretty-printed file SHA; do not treat the two digest definitions as a mismatch.
4. Published integer percentages for nemolizumab, abrocitinib, and dupilumab are intentionally preserved as source-reported values rather than recomputed to artificial decimal precision. Numerator/denominator remain visible separately.
5. Baricitinib preserves the published 58%/54% but leaves n/N unreported; the product requirement permits an explicitly marked missing n/N when a public source reports only the rate. Do not require inferred counts.
6. Tapinarof's source table labels the row `Any AEs`; the primary study describes safety assessment as incidence/frequency of TEAEs. It is normalized to `任何TEAE` while the original label remains in the locator/original text. Decide whether that is scientifically acceptable or identify a concrete contradictory source.
7. Recompute coverage precisely: efficacy numeric products, any safety numeric products, treatment-arm exact TEAE products, and paired exact TEAE products. Do not call 20 treatment-arm products 20 paired products.

Read no other participant output. Do not edit files. Return complete updated Markdown for your role, separating evidence, inference, recommendation, and uncertainty. Codex remains final authority.
